critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic
Search Results
HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.
Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra
Advances in the Treatment of Non-Small Cell Lung Cancer
Leora Horn
guidelines, maintenance therapy is an option for select patients with tumor response or stable disease and is not considered the standard of care for all patients. Category 1 options in continuation maintenance therapy include single-agent bevacizumab and
Oncology Research Program
Bendamustine and Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Condition: Advanced cancers Institution: The University of Texas MD Anderson Cancer Center, Houston, Texas Bendamustine is
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Presented by: Dustin A. Deming
molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR
Use of PARP Inhibitors for Ovarian Cancer
Presented by: Deborah K. Armstrong
enrolled patients with newly diagnosed, stage III–IV, high-grade serous/endometrioid ovarian, fallopian tube, or primary peritoneal cancer. 2 All subjects had to have undergone ≥3 cycles of bevacizumab with their initial chemotherapy. At the end of
NCCN News
NCCN Breast Cancer Panel Reaffirms Current Position and Recommendation Regarding the Use of Bevacizumab in Metastatic Breast Cancer The Expert Breast Cancer Panel of the NCCN met July 10–12, 2011, in Philadelphia, Pennsylvania. The
Ovarian Cancer, Version 2.2013
Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes
treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease (mainly epithelial ovarian cancer), and 6) management of drug/hypersensitivity reactions. 1
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes
NSCLC, including pembrolizumab monotherapy, pembrolizumab/chemotherapy, and atezolizumab/bevacizumab/chemotherapy. 13 – 20 These NCCN Guidelines Insights focus on recent updates in immunotherapy for eligible patients with metastatic NSCLC. Furthermore
Metastatic Colon Cancer, Version 3.2013
Featured Updates to the NCCN Guidelines
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
hand, the prospective, multicenter phase II NSABP C-10 trial showed that patients with an asymptomatic primary colon tumor and unresectable metastatic disease who received mFOLFOX6 with bevacizumab experienced an acceptable level of morbidity without
Ten Years of Progress in Colon Cancer Therapy
Paul F. Engstrom
that FOLFOX for 6 months was superior to 5-FU/leucovorin as adjuvant therapy for patients with stage III colon cancer. 1 In 2004, antibody therapy of colon cancer became a reality with the discovery that bevacizumab selectively inhibited tumor